GT Biopharma Demonstrates Novel B7-H3 Targeting Dual Camelid Nanobody BiKE and GTB-5550 Induce NK Cell Activation Against Broad Spectrum of Tumors at ESMO IO Congress 2021
/PRNewswire/ GT Biopharma, Inc. (the "Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based.
/PRNewswire/ GT Biopharma, Inc. (the "Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based.